Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2008 1
2009 7
2010 6
2011 2
2012 3
2013 5
2014 7
2015 6
2016 1
2017 1
2019 2
2020 1
2021 3
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

43 results
Results by year
Filters applied: . Clear all
Page 1
Novel therapeutic targets for multiple myeloma.
Mahindra A, Cirstea D, Raje N. Mahindra A, et al. Among authors: cirstea d. Future Oncol. 2010 Mar;6(3):407-18. doi: 10.2217/fon.10.2. Future Oncol. 2010. PMID: 20222797 Review.
CSNK1α1 mediates malignant plasma cell survival.
Hu Y, Song W, Cirstea D, Lu D, Munshi NC, Anderson KC. Hu Y, et al. Among authors: cirstea d. Leukemia. 2015 Feb;29(2):474-82. doi: 10.1038/leu.2014.202. Epub 2014 Jun 25. Leukemia. 2015. PMID: 24962017 Free PMC article.
With equal access, African American patients have superior survival compared to white patients with multiple myeloma: a VA study.
Fillmore NR, Yellapragada SV, Ifeorah C, Mehta A, Cirstea D, White PS, Rivero G, Zimolzak A, Pyarajan S, Do N, Brophy M, Munshi NC. Fillmore NR, et al. Among authors: cirstea d. Blood. 2019 Jun 13;133(24):2615-2618. doi: 10.1182/blood.2019000406. Epub 2019 Apr 19. Blood. 2019. PMID: 31003998 Free PMC article. No abstract available.
Anti-tumor activities of selective HSP90α/β inhibitor, TAS-116, in combination with bortezomib in multiple myeloma.
Suzuki R, Hideshima T, Mimura N, Minami J, Ohguchi H, Kikuchi S, Yoshida Y, Gorgun G, Cirstea D, Cottini F, Jakubikova J, Tai YT, Chauhan D, Richardson PG, Munshi NC, Utsugi T, Anderson KC. Suzuki R, et al. Among authors: cirstea d. Leukemia. 2015 Feb;29(2):510-4. doi: 10.1038/leu.2014.300. Epub 2014 Oct 13. Leukemia. 2015. PMID: 25306900 Free PMC article. No abstract available.
Correction: Dual Inhibition of Canonical and Noncanonical NF-κB Pathways Demonstrates Significant Antitumor Activities in Multiple Myeloma.
Fabre C, Mimura N, Bobb K, Kong SY, Gorgun G, Cirstea D, Hu Y, Minami J, Ohguchi H, Zhang J, Meshulam J, Carrasco RD, Tai YT, Richardson PG, Hideshima T, Anderson KC. Fabre C, et al. Among authors: cirstea d. Clin Cancer Res. 2019 May 1;25(9):2938. doi: 10.1158/1078-0432.CCR-19-0959. Clin Cancer Res. 2019. PMID: 31043386 Free article. No abstract available.
Role of decorin in multiple myeloma (MM) bone marrow microenvironment.
Nemani N, Santo L, Eda H, Cirstea D, Mishima Y, Patel C, O'Donnell E, Yee A, Raje N. Nemani N, et al. Among authors: cirstea d. J Bone Miner Res. 2015 Mar;30(3):465-70. doi: 10.1002/jbmr.2371. J Bone Miner Res. 2015. PMID: 25407518 Free article.
43 results